The FDA approved epoetin alfa-epbx (Retacrit, Pfizer) as a biosimilar to Epogen/Procrit (epoetin alfa; Amgen) to treat anemia caused by chemotherapy, chronic kidney disease, or use of zidovudine in patients with HIV infection. It also is approved for use before and after surgery to reduce the chance that transfusions will be needed because of blood loss during surgery. Epoetin alfa-epbx is approved as a biosimilar, not an interchangeable product.